Skip to content

A Trial of a Comprehensive Breast Cancer Treatment Patient Decision Tool

Individualizing Decision Quality for Patients With Breast Cancer: A RCT of a Comprehensive Breast Cancer Treatment Patient Decision Tool

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01840163
Enrollment
537
Registered
2013-04-25
Start date
2014-02-28
Completion date
2017-09-01
Last updated
2018-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This study examines the impact of an online decision tool for patients with early stage invasive breast cancer. The study is a randomized controlled trial (RCT) of 444 newly diagnosed patients, recruited from multiple surgical practices in two SEER catchment areas. Participants will be randomized to receive either a basic version of a decision tool (similar to existing website with breast cancer information) or an enhanced version (featuring a knowledge building component, a values clarification exercise, and a patient activation module). Our hypothesis is that patients who use the enhanced version of the tool will have greater knowledge of their test and treatment options, have a higher rate of high quality (i.e., informed, preference-concordant) decisions, and report more positive appraisal of the decision-making process.

Detailed description

Patients newly diagnosed with breast cancer face a series of complex decisions regarding locoregional and systemic treatment. Currently many of these decisions do not meet the definition of a high quality decision, defined as one that is both informed (i.e., based on an accurate understanding of the treatment risks and benefits) and preference-concordant (i.e., consistent with the patients' underlying preferences). Moreover, the introduction of evaluative tests has made these decisions more complicated for many patients. There is a need to improve the quality of locoregional and systemic treatment decisions for breast cancer patients, and to help patients understand the role of evaluative tests in this decision process. Ensuring patients can deliberate effectively about these decisions, assert their views and communicate with their clinicians is likely to improve their overall decision preparedness and satisfaction. This study will focus on the third pillar of individualized care by evaluating the impact of an innovative decision tool on locoregional and systemic therapy decision making for newly diagnosed breast cancer patients. The innovative online decision tool has been developed and tested over the past two years by the CanSORT team (R21 CA129859). Pilot data suggests that this tool has a positive impact on patient knowledge and decision outcomes. The goal of this study is to evaluate the impact of this tool, after it is enhanced in collaboration with our Communication and Dissemination Core, on the quality of decision making for locoregional and systemic breast cancer treatment decision making.

Interventions

OTHERStatic version of CanSORT tool
OTHERCanSORT Online Tool

Sponsors

Emory University
CollaboratorOTHER
University of Michigan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 84 Years
Healthy volunteers
No

Inclusion criteria

* Stage 1-2 invasive breast cancer diagnosis, * DCIS * Ability to read English

Exclusion criteria

* Male

Design outcomes

Primary

MeasureTime frameDescription
Number of Patients With Accurate Knowledge About Risks and Benefits of Treatment Options for Locoregional Breast Cancer.4-5 weeks from date of enrollmentSelf reported knowledge about locoregional treatment using a 5 item Breast Cancer Knowledge Measure (adapted). A binary knowledge indicator was created for all patients whereby high knowledge indicated for patients scoring greater than 80% on the item scale. The binary knowledge variable was analyzed for intervention effect using both unadjusted and adjusted logistic mixed model regression.
Number of Patients Choosing a Treatment Option for Locoregional Treatment That Was Values Concordant4-5 weeks from date of enrollmentSelf reported values were evaluated using a 5 item question set adapted from Decision Quality Instrument. The questions determined patient desire for outcomes such as keeping their natural breast and avoiding radiation on a scale from 0 to 10. Patients were classified as values-concordant if their actual treatment aligned with their values score predicted treatment and otherwise were classified as non-concordant. The binary values-concordance variable was modeled as a function of intervention effect using both unadjusted and adjusted logistic mixed model regression.

Secondary

MeasureTime frameDescription
Patient Subjective Decision Quality for Locoregional Breast Cancer Treatment4-5 weeks from date of enrollmentA 5 item subjective decision quality scale measured how satisfied patients were with their treatment decision. Patients were asked how well they agreed with 5 statements, with responses of 'not at all'/'a little bit'/'somewhat'/'quite a bit'/'very much'. All responses were assigned values from 1 to 5, with higher values reflecting greater decision satisfaction. Two of the statements reflected satisfaction with the decision and were coded as 1 for 'not at all' through 5 for 'very much'. The other three statements reflected dissatisfaction with the decision and were coded as 5 for 'not at all' through 1 for 'very much' The values of all 5 items were combined using the arithmetic mean, to create a standardized scale ranging from 1 (not at all) to 5 (very much). The subjective decision quality scale was modeled by linear mixed model to determine the effect of intervention on patient response.
Number of Patients With Accurate Knowledge About Risks and Benefits of Systemic Treatment Options for Breast Cancer9 months after enrollmentSelf-reported knowledge about systemic treatment using a 5 item Breast Cancer Knowledge Measure (adapted) consisting of 5 questions to test patients' knowledge about systemic treatment options for breast cancer. We compared the number of patients who gave correct answers to at least 80% of the questions between two groups. We used both unadjusted and adjusted generalized linear mixed models with logit as the link function.
Patient Preparedness Decision Making for Locoregional Treatment.4-5 weeks from date of enrollmentA 12 item decision preparedness scale asked whether the web intervention helped patients prepare for their treatment decision. Each item asked about a diefferent aspect of decision preparation, with responses of 'not at all'/'a little'/'somewhat'/'quite a bit'/'a great deal'. Each response was assigned a value of 1('not at all') to 5('a great deal'), with a high value representing a greater amount of preparedness. The values of all 12 items were combined using the arithmetic mean, to create a standardized scale ranging from 1(not at all) to 5 (a great deal). The decision making scale was modeled by linear mixed model to determine the effect intervention on patient preparation for decision making.
Patient Subjective Decision Quality for Systemic Breast Cancer Treatment9 months after enrollmentA 4 item subjective decision quality scale measured how satisfied patients were with their chemotherapy treatment decision. Patients were asked to rate the amounts of information, involvement, time, and overall satisfaction associated with their chemotherapy decisions. Possible responses ranged from 'not enough' to 'just right' to 'too much'. All responses were assigned values from 1 to 5, with a response of 'just right' coded as 5 points, and both 'not enough' and 'too much' coded as 1 point. The values of all 4 items were combined using the arithmetic mean, to create a standardized scale ranging from 1 (low decision quality) to 5 (high decision quality). The subjective decision quality scale was used as an outcome in linear mixed models to determine the effect of intervention on patient decision quality.
Patient Preparedness Decision Making for Systemic Treatment9 months after enrollmentA 10-item decision preparedness scale asked whether the web intervention helped patients prepare for their treatment decision. Each item asked about a different aspect of decision preparation, with responses of 'not at all'/'a little'/'somewhat'/'quite a bit'/'a great deal'. Each response was assigned a value of 1('not at all') to 5('a great deal'), with a high value representing a greater amount of preparedness. The values of all 10 items were combined using the arithmetic mean, to create a standardized scale ranging from 1(not at all) to 5 (a great deal). The decision making scale was modeled by linear mixed model to determine the effect intervention on patient preparation for decision making.
Patient Deliberation for Locoregional Breast Cancer Treatment.4-5 weeks from date of enrollmentA 4 item Breast Cancer Treatment Deliberation Scale asked how deliberative patients were in making their treatment decision. The items asked how often they performed deliberative activities with answers of 'not at all'/'a little'/'somewhat'/'quite a bit'/'a lot'. Each response was assigned a value of 1('not at all') to 5('a lot), with a high value representing a greater amount of deliberation. The values of all 4 items were combined using the arithmetic mean, to create a standardized scale ranging from 1 (not at all) to 5 (a lot). The deliberation scale was then modeled using linear mixed models to determine the effect of the intervention on patient deliberation.

Countries

United States

Participant flow

Participants by arm

ArmCount
CanSORT Online Tool (Intervention)
Comprehensive (interactive) version of decision tool CanSORT Online Tool
267
Static Version of CanSORT Tool (Control)
Static version (non-interactive) version of CanSORT decision tool Static version of CanSORT tool
270
Total537

Withdrawals & dropouts

PeriodReasonFG000FG001
First Follow up -Primary OutcomeLost to Follow-up1916
Systemic Follow Up-secondary Outcomeexcluded -DCIS not eligible4335
Systemic Follow Up-secondary OutcomeLost to Follow-up4840

Baseline characteristics

CharacteristicCanSORT Online Tool (Intervention)TotalStatic Version of CanSORT Tool (Control)
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
59 Participants121 Participants62 Participants
Age, Categorical
Between 18 and 65 years
208 Participants416 Participants208 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants8 Participants5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
264 Participants529 Participants265 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Number of participants leaning towards a treatment option and felt sure about choice178 Participants353 Participants175 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants2 Participants0 Participants
Race (NIH/OMB)
Asian
8 Participants15 Participants7 Participants
Race (NIH/OMB)
Black or African American
42 Participants86 Participants44 Participants
Race (NIH/OMB)
More than one race
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants8 Participants4 Participants
Race (NIH/OMB)
White
211 Participants425 Participants214 Participants
Region of Enrollment
United States
267 participants537 participants270 participants
Sex: Female, Male
Female
267 Participants537 Participants270 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 2670 / 270
other
Total, other adverse events
0 / 2670 / 270
serious
Total, serious adverse events
0 / 2670 / 270

Outcome results

Primary

Number of Patients Choosing a Treatment Option for Locoregional Treatment That Was Values Concordant

Self reported values were evaluated using a 5 item question set adapted from Decision Quality Instrument. The questions determined patient desire for outcomes such as keeping their natural breast and avoiding radiation on a scale from 0 to 10. Patients were classified as values-concordant if their actual treatment aligned with their values score predicted treatment and otherwise were classified as non-concordant. The binary values-concordance variable was modeled as a function of intervention effect using both unadjusted and adjusted logistic mixed model regression.

Time frame: 4-5 weeks from date of enrollment

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CanSORT Online Tool (Intervention)Number of Patients Choosing a Treatment Option for Locoregional Treatment That Was Values Concordant180 Participants
Static Version of CanSORT Tool (Control)Number of Patients Choosing a Treatment Option for Locoregional Treatment That Was Values Concordant197 Participants
Primary

Number of Patients With Accurate Knowledge About Risks and Benefits of Treatment Options for Locoregional Breast Cancer.

Self reported knowledge about locoregional treatment using a 5 item Breast Cancer Knowledge Measure (adapted). A binary knowledge indicator was created for all patients whereby high knowledge indicated for patients scoring greater than 80% on the item scale. The binary knowledge variable was analyzed for intervention effect using both unadjusted and adjusted logistic mixed model regression.

Time frame: 4-5 weeks from date of enrollment

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CanSORT Online Tool (Intervention)Number of Patients With Accurate Knowledge About Risks and Benefits of Treatment Options for Locoregional Breast Cancer.148 Participants
Static Version of CanSORT Tool (Control)Number of Patients With Accurate Knowledge About Risks and Benefits of Treatment Options for Locoregional Breast Cancer.105 Participants
Secondary

Number of Patients With Accurate Knowledge About Risks and Benefits of Systemic Treatment Options for Breast Cancer

Self-reported knowledge about systemic treatment using a 5 item Breast Cancer Knowledge Measure (adapted) consisting of 5 questions to test patients' knowledge about systemic treatment options for breast cancer. We compared the number of patients who gave correct answers to at least 80% of the questions between two groups. We used both unadjusted and adjusted generalized linear mixed models with logit as the link function.

Time frame: 9 months after enrollment

Population: The numbers analyzed for these secondary outcomes were taken from the study's systemic portion of the study which took place 9 months after enrollment at which point response rate dropped and therefore numbers are less than those for primary outcomes which were done 4-5 weeks after enrollment.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CanSORT Online Tool (Intervention)Number of Patients With Accurate Knowledge About Risks and Benefits of Systemic Treatment Options for Breast Cancer55 Participants
Static Version of CanSORT Tool (Control)Number of Patients With Accurate Knowledge About Risks and Benefits of Systemic Treatment Options for Breast Cancer43 Participants
Secondary

Patient Deliberation for Locoregional Breast Cancer Treatment.

A 4 item Breast Cancer Treatment Deliberation Scale asked how deliberative patients were in making their treatment decision. The items asked how often they performed deliberative activities with answers of 'not at all'/'a little'/'somewhat'/'quite a bit'/'a lot'. Each response was assigned a value of 1('not at all') to 5('a lot), with a high value representing a greater amount of deliberation. The values of all 4 items were combined using the arithmetic mean, to create a standardized scale ranging from 1 (not at all) to 5 (a lot). The deliberation scale was then modeled using linear mixed models to determine the effect of the intervention on patient deliberation.

Time frame: 4-5 weeks from date of enrollment

Population: participants

ArmMeasureValue (MEAN)Dispersion
CanSORT Online Tool (Intervention)Patient Deliberation for Locoregional Breast Cancer Treatment.3.9 units on a scaleStandard Deviation 0.8
Static Version of CanSORT Tool (Control)Patient Deliberation for Locoregional Breast Cancer Treatment.3.7 units on a scaleStandard Deviation 0.9
Secondary

Patient Preparedness Decision Making for Locoregional Treatment.

A 12 item decision preparedness scale asked whether the web intervention helped patients prepare for their treatment decision. Each item asked about a diefferent aspect of decision preparation, with responses of 'not at all'/'a little'/'somewhat'/'quite a bit'/'a great deal'. Each response was assigned a value of 1('not at all') to 5('a great deal'), with a high value representing a greater amount of preparedness. The values of all 12 items were combined using the arithmetic mean, to create a standardized scale ranging from 1(not at all) to 5 (a great deal). The decision making scale was modeled by linear mixed model to determine the effect intervention on patient preparation for decision making.

Time frame: 4-5 weeks from date of enrollment

ArmMeasureValue (MEAN)Dispersion
CanSORT Online Tool (Intervention)Patient Preparedness Decision Making for Locoregional Treatment.3.9 units on a scaleStandard Deviation 0.9
Static Version of CanSORT Tool (Control)Patient Preparedness Decision Making for Locoregional Treatment.3.7 units on a scaleStandard Deviation 0.9
Secondary

Patient Preparedness Decision Making for Systemic Treatment

A 10-item decision preparedness scale asked whether the web intervention helped patients prepare for their treatment decision. Each item asked about a different aspect of decision preparation, with responses of 'not at all'/'a little'/'somewhat'/'quite a bit'/'a great deal'. Each response was assigned a value of 1('not at all') to 5('a great deal'), with a high value representing a greater amount of preparedness. The values of all 10 items were combined using the arithmetic mean, to create a standardized scale ranging from 1(not at all) to 5 (a great deal). The decision making scale was modeled by linear mixed model to determine the effect intervention on patient preparation for decision making.

Time frame: 9 months after enrollment

ArmMeasureValue (MEAN)Dispersion
CanSORT Online Tool (Intervention)Patient Preparedness Decision Making for Systemic Treatment3.76 units on a scaleStandard Deviation 0.96
Static Version of CanSORT Tool (Control)Patient Preparedness Decision Making for Systemic Treatment3.61 units on a scaleStandard Deviation 1.07
Secondary

Patient Subjective Decision Quality for Locoregional Breast Cancer Treatment

A 5 item subjective decision quality scale measured how satisfied patients were with their treatment decision. Patients were asked how well they agreed with 5 statements, with responses of 'not at all'/'a little bit'/'somewhat'/'quite a bit'/'very much'. All responses were assigned values from 1 to 5, with higher values reflecting greater decision satisfaction. Two of the statements reflected satisfaction with the decision and were coded as 1 for 'not at all' through 5 for 'very much'. The other three statements reflected dissatisfaction with the decision and were coded as 5 for 'not at all' through 1 for 'very much' The values of all 5 items were combined using the arithmetic mean, to create a standardized scale ranging from 1 (not at all) to 5 (very much). The subjective decision quality scale was modeled by linear mixed model to determine the effect of intervention on patient response.

Time frame: 4-5 weeks from date of enrollment

ArmMeasureValue (MEAN)Dispersion
CanSORT Online Tool (Intervention)Patient Subjective Decision Quality for Locoregional Breast Cancer Treatment4.5 units on a scaleStandard Deviation 0.5
Static Version of CanSORT Tool (Control)Patient Subjective Decision Quality for Locoregional Breast Cancer Treatment4.4 units on a scaleStandard Deviation 0.6
Secondary

Patient Subjective Decision Quality for Systemic Breast Cancer Treatment

A 4 item subjective decision quality scale measured how satisfied patients were with their chemotherapy treatment decision. Patients were asked to rate the amounts of information, involvement, time, and overall satisfaction associated with their chemotherapy decisions. Possible responses ranged from 'not enough' to 'just right' to 'too much'. All responses were assigned values from 1 to 5, with a response of 'just right' coded as 5 points, and both 'not enough' and 'too much' coded as 1 point. The values of all 4 items were combined using the arithmetic mean, to create a standardized scale ranging from 1 (low decision quality) to 5 (high decision quality). The subjective decision quality scale was used as an outcome in linear mixed models to determine the effect of intervention on patient decision quality.

Time frame: 9 months after enrollment

ArmMeasureValue (MEAN)Dispersion
CanSORT Online Tool (Intervention)Patient Subjective Decision Quality for Systemic Breast Cancer Treatment3.61 units on a scaleStandard Deviation 1.07
Static Version of CanSORT Tool (Control)Patient Subjective Decision Quality for Systemic Breast Cancer Treatment3.76 units on a scaleStandard Deviation 0.96

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026